Effect of berberine on lipid metabolism and atherosclerosis of atherosclerotic rabbits

Chinese Journal of Biologicals

Volumn 25, Issue 2, 2012, Pages

  Luo, Ying ^a   He, Qi ^a   Jin, Lei ^a   Zhou, Qi Xin ^a   Yang, Jun Xia ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Atherosclerosis; Berberine; Inducible nitric oxide synthase (iNOS); Lipid metabolism; PPAR

Indexed keywords

BERBERINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDUCIBLE NITRIC OXIDE SYNTHASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; HISTOLOGY; IN VIVO STUDY; LIPID METABOLISM; NONHUMAN; PROTEIN EXPRESSION; RABBIT; REAL TIME POLYMERASE CHAIN REACTION; TRIACYLGLYCEROL BLOOD LEVEL;

ORYCTOLAGUS CUNICULUS;

EID: 84863372203     PISSN: 10045503     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Smirnov AN. Lipid signaling in the atherogenesis context [J]. Biochemistry (Mosc), 2010, 75 (7): 793-810.
2. Perrotta I, Brunelli E, Sciangula A, et al. Inducible and endothelial nitric oxide synthase expression in human atherogenesis: an immunohistochemical and ultrastructural study [Jl Cardiovasc Pathol, 2009, 18 (6): 361-368.
3. Sugawara A, Uruno A, Kudo M, et al. Effects of PPARγ on hypertension, atherosclerosis, and chronic kidney disease [J]. Endocr J, 2010, 57 (10): 847-852.
4. Sueyoshi S, Mitsumata M, Kusumi Y, et al. Increased expression of peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ in human atherosclerosis [J]. Pathol Res Prac, 2010, 206 (7): 429-438.
5. Kong W, Wei J, Abidi P, et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins [J]. Nat Med, 2004, 10 (12): 1344-1351. (Pubitemid 40022716)
6. Brusq JM, Amcellin N, Grondin P, et al. Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of Berberine [J]. J Lipid Res, 2006, 47 (6): 1281-1288. (Pubitemid 43830720)
7. Kuo CL, Chi CW, Liu TY. The anti-inflammatory potential of berberine in vitro and in vivo [J]. Cancer Lett, 2004, 203 (2): 127-137.
8. Hsiang CY, Wu SL, Cheng SE, et al. Acetaldehyde-induced interleukin-1beta and tumor necrosis factor- alpha production is inhibited by berberine through nuclear factor-kappaB signaling pathway in HepG2 cells [J]. J Biomed Sci, 2005, 12 (5): 791-801.
9. Knott AB, Bossy-Wetzel E. Impact of nitric oxide on metabolism in health and age-related disease [J]. Diabetes Obes Metab, 2010, 12 (Suppl 2): 126-133.
10. Schmidt MV, Brüne B, Von Knethen A. The nuclear hormone receptor PPARγ as a therapeutic target in major diseases [J]. Sci World J, 2010, 10: 2181-2197.
11. Rieusset J, Touri F, Michalik L, et al. A new selective peroxisome proliferator-activated receptor gamma antagonist with antiobesity and antidiabetic activity [J]. Mol Endocrinol, 2002, 16 (11): 2628-2644. (Pubitemid 35266080)
12. Huang C, Zhang Y, Gong Z, et al. Berberine inhibits 3T3-L1 adipocyte differentiation through the PPARgamma pathway [J]. Biochem Biophys Res Commun, 2006, 348 (2): 571-578. (Pubitemid 44209153)